Lymphocyte Homing Antagonists in the Treatment of Inflammatory Bowel Diseases

• Autores: Brigid S. Boland, William J. Sandborn, John T. Chang
• Localización: Gastroenterology clinics of North America, ISSN 0889-8553, Vol. 43, Nº. 3, 2014 (Ejemplar dedicado a: Biologics in Inflammatory Bowel Disease), págs. 581-601
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Janus kinase (JAK) inhibitors have emerged as a novel orally administered small-molecule therapy for the treatment of ulcerative colitis and possibly Crohn disease. These molecules are designed to selectively target the activity of specific JAKs and to offer a targeted mechanism of action without risk of immunogenicity. Based on data from clinical trials in rheumatoid arthritis and phase 2 studies in inflammatory bowel disease, tofacitinib and other JAK inhibitors are likely to become a new form of medical therapy for the treatment of inflammatory bowel disease.